Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUTIS BIOTHERAPEUTICS, INC.

(ARQT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Seborrheic Dermatitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma A/S Amorepacific and Other

04/16/2021 | 03:40am EDT

Seborrheic dermatitis is a chronic inflammatory dermatologic condition that usually affects the areas of the body with a large density of sebaceous glands, such as the scalp, face, chest, back, axilla, and groin. Overall, it has been reported to affect about 4% of the population. The cause of seborrheic dermatitis is not completely understood but it is thought to be triggered by the overgrowth of a harmless yeast called Malassezia that lives on the skin, or an overreaction by the skin's immune system to this yeast. The diagnosis is based on the location and appearance of rash or lesion. Skin biopsy may be helpful but is rarely indicated. Seborrhoeic dermatitis is managed with treatment that reduces the level of skin yeast - these include creams and shampoo, which can be used safely on a long-term basis.

DelveInsight's, "Seborrhoeic Dermatitis Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight

Some of Seborrhoeic Dermatitis Companies are:*Arcutis Biotherapeutics *Cutanea Life Sciences *DermBiont *Astion Pharma A/S *Amorepacific *And Many Others

Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight

Current Seborrhoeic Dermatitis Treatment Scenario and Seborrhoeic Dermatitis Emerging Therapies:*How many companies are developing Seborrhoeic Dermatitis drugs? *How many Seborrhoeic Dermatitis drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seborrhoeic Dermatitis? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seborrhoeic Dermatitis therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Seborrhoeic Dermatitis and their status? *What are the key designations that have been granted to the emerging drugs?

Some of Seborrhoeic Dermatitis Therapies are:*Topical roflumilast foam (ARQ-154) *Omiganan (CLS002) *DBI-002 *PAC-14028 *And Many Others

Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight

Table of Contents:

Introduction

Executive Summary

Seborrhoeic Dermatitis: Overview

Pipeline Therapeutics*Comparative Analysis

Therapeutic Assessment

Seborrhoeic Dermatitis - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Seborrhoeic Dermatitis Collaboration Deals

Late Stage Products (Phase III)

ASF 1057: Astion Pharma A/S

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)*Comparative Analysis

ARQ-154: Arcutis Biotherapeutics

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

DBI-002: Dermbiont

Drug profiles in the detailed report.....

Inactive Products

Seborrhoeic Dermatitis Key Companies

Seborrhoeic Dermatitis Key Products

Seborrhoeic Dermatitis- Unmet Needs

Seborrhoeic Dermatitis- Market Drivers and Barriers

Seborrhoeic Dermatitis- Future Perspectives and Conclusion

Seborrhoeic Dermatitis Analyst Views

Seborrhoeic Dermatitis Key Companies

Appendix

Request for Deatiled TOC: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
AMOREPACIFIC GROUP 4.83% 52100 End-of-day quote.-5.10%
ARCUTIS BIOTHERAPEUTICS, INC. -1.85% 22.28 Delayed Quote.-20.80%
All news about ARCUTIS BIOTHERAPEUTICS, INC.
10/04ARCUTIS BIOTHERAPEUTICS : Submits New Drug Application for Psoriasis Topical Treatment
MT
10/04ARCUTIS BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
10/04ARCUTIS BIOTHERAPEUTICS : Submits Topical Roflumilast Cream New Drug Application to FDA fo..
AQ
10/04Arcutis Biotherapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Admini..
CI
09/30ARCUTIS BIOTHERAPEUTICS : New Data Highlighting Itch Reduction with Topical Roflumilast in..
GL
09/30Arcutis Biotherapeutics, Inc. Announces New Data Highlighting Itch Reduction with Topic..
CI
09/30Arcutis Biotherapeutics, Inc. Announces New Patient-Reported Outcome Data That Show Top..
CI
09/28ARCUTIS BIOTHERAPEUTICS : Expands Patent Portfolio with Roflumilast Pharmacokinetics Paten..
AQ
09/28ARCUTIS BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Stat..
AQ
09/27New Topical Roflumilast Data Presented at the European Academy of Dermatology and Vener..
GL
More news
Analyst Recommendations on ARCUTIS BIOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -218 M - -
Net cash 2021 328 M - -
P/E ratio 2021 -5,02x
Yield 2021 -
Capitalization 1 119 M 1 119 M -
EV / Sales 2021 -
EV / Sales 2022 96,0x
Nbr of Employees 108
Free-Float 94,7%
Chart ARCUTIS BIOTHERAPEUTICS, INC.
Duration : Period :
Arcutis Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUTIS BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 22,28 $
Average target price 56,43 $
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Todd Franklin Watanabe President, Chief Executive Officer & Director
Scott L. Burrows Chief Financial & Accounting Officer
Patrick J. Heron Chairman
David W. Osborne Chief Technical Officer
David Berk Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUTIS BIOTHERAPEUTICS, INC.-20.80%1 119
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156